Thu, Apr 17, 2014, 5:56 AM EDT - U.S. Markets open in 3 hrs 34 mins

Recent

% | $
Quotes you view appear here for quick access.

Stryker Corporation Message Board

andy55q 78 posts  |  Last Activity: 10 hours ago Member since: Feb 2, 2006
  • Presentation of Case
    A well-nourished 77-year-old man whose medical history includes treated hypertension and hypercholesterolemia, previous heavy alcohol intake, and mild cognitive impairment is admitted to the intensive care unit (ICU) of a university hospital from the operating room after a Hartmann’s procedure (resection of the rectosigmoid colon with closure of the rectal stump and formation of an end colostomy) performed for fecal peritonitis due to a perforated sigmoid colon. On arrival in the ICU, he was in septic shock. He is undergoing mechanical ventilation with the use of a low-tidal-volume protocol with positive end-expiratory pressure (PEEP). His arterial blood pressure is supported with a norepinephrine infusion. Analgesia is provided by a continuous morphine infusion. Enteral nutrition was started on the day after ICU admission, and target intake was achieved on day 6. Parenteral nutrition was not used. (In theprevious installment of this case, there were 2906 votes on strategies for feeding this critically ill patient. A majority of respondents [53%] favored initiating enteral nutrition within 24 to 48 hours after ICU admission and then starting parenteral nutrition on day 7 if the caloric target was not being met. Another 30% favored initiating parenteral nutrition as soon as possible after the patient’s arrival in the ICU and then starting enteral nutrition once bowel sounds return, whereas 11% favored awaiting the return of bowel sounds and then initiating enteral nutrition. Only 4% favored initiating total parenteral nutrition as soon as possible after the patient’s arrival in the ICU.)
    Question
    Since it is likely that this patient will have a prolonged stay in the ICU, what measures would you take to optimize his long-term recovery? Participate in the poll and, if you like, submit a comment supporting your choice. The editors’ recommendations will appear here, along with a link to the related review article, on April 24.

    Sentiment: Buy

  • Reply to

    5 More Products

    by z3peru 21 hours ago

    CytoSorbents and University of Pennsylvania Vet School Collaborate to Expand CytoSorb(R) Research in Cancer Immunotherapy

    Sentiment: Buy

  • Reply to

    Like it or not we're on the way.

    by shortsaretoast Apr 11, 2014 12:28 PM
    andy55q andy55q Apr 11, 2014 3:37 PM Flag

    Right-on Jake

    Sentiment: Buy

  • This study is currently recruiting participants.
    Verified April 2014 by CytoSorbents, Inc
    Sponsor:
    CytoSorbents, Inc
    Collaborator:
    San Antonio Military Medical Center (SAMMC), US Army Institute of Surgical Research-Burn Center
    Information provided by (Responsible Party):
    CytoSorbents, Inc
    ClinicalTrials.gov Identifier:
    NCT02111018
    First received: March 19, 2014
    Last updated: April 7, 2014
    Last verified: April 2014
    History of Changes

    Sentiment: Buy

  • andy55q andy55q Apr 10, 2014 1:09 PM Flag

    Cytokine Removal in Cardiopulmonary Bypass Patients (CytoSorb)
    This study is currently recruiting participants.
    Verified November 2013 by Medical University of Vienna
    Sponsor:
    Medical University of Vienna
    Collaborator:
    CytoSorbents Europe GmbH
    Information provided by (Responsible Party):
    Dr. Martin Bernardi, Medical University of Vienna
    ClinicalTrials.gov Identifier:
    NCT01879176
    First received: June 7, 2013
    Last updated: November 1, 2013
    Last verified: November 2013
    History of Changes

    Sentiment: Buy

  • Reply to

    To buymyask

    by dah174174 Apr 8, 2014 3:00 PM
    andy55q andy55q Apr 8, 2014 8:48 PM Flag

    Snow - I agree with you that this is one of the most important questions that needs to be asked. I am hoping he will give me some information but I cant guarantee anything. Thats pretty much asking him if he can provide me with a private revenue growth guidance for Q2 Q3 and Q4 - which is non public information obviously.

    I am mainly going to ask him about:

    1.) Future sales growth rates (can we keep 50%+ QoQ growth rate?)
    2.) Amount of time between enrollment completion in FDA trial from when we hear about results from when the FDA decides to clear product or not
    3.) What factors will come into play when FDA decides to clear product or not (ie: what risks do we have for not getting clearance)
    4.) Who were the institutions that bought 40m shares - I want names of companies so i can DD them. If they are Warren Buffet value investing thats good - if they are LPC sharks that will make me very angry
    5.) When will data from patient registry be disclosed to public and what type of information is being collected. Additionally, what are the controls are who is allowed to collect information (ie: will this registry data be viewed as credible by medical community)
    6.) When do you believe the cash on balance sheet will run out and we will have to do another offering (this could be 1-2 years because FDA expense is large and will burn cash)
    7.) Do you expect any of the CTSO pipeline of products to generate significant revenue for the company in the next 1-2 years

    Let me know if there is anything I should add. I am not discussing up listing with him because i still feel that thats a joke.
    Cpbball3 Saturday, 04/05/14 11:47:39 AM
    Re: snow post# 4989
    Post # of 5008

    Sentiment: Buy

  • Reply to

    To buymyask

    by dah174174 Apr 8, 2014 3:00 PM
    andy55q andy55q Apr 8, 2014 4:25 PM Flag

    What day/date on IHUB Post#

  • andy55q andy55q Apr 8, 2014 8:41 AM Flag

    Middle East respiratory syndrome coronavirus (MERS-CoV) – update

    Disease Outbreak News

    27 MARCH 2014 - On 20 and 21 March 2014, the Ministry of Health of Saudi Arabia announced an additional six laboratory-confirmed cases of infection with Middle East respiratory syndrome coronavirus (MERS-CoV).

    Details of the cases provided to WHO are as follows:
    A 71 year-old man from the Riyadh region with underlying medical conditions. He became ill on 24 February and was admitted to hospital on 5 March. He is currently in a critical condition. The patient had a history of exposure to animals, including camels.
    A 66 year-old man from the Riyadh region with underlying medical conditions. He became ill on 9 March and was admitted to hospital on 11 March. He is currently in a critical condition. The patient had no history of exposure to animals.
    An 86 year-old man from the Riyadh region. He became ill on 11 March and passed away on 19 March. He had no history of exposure to animals.
    A 75 year-old man from the Riyadh region with underlying medical conditions. He became ill on 23 February and was admitted to hospital on 26 February. He is currently in a critical condition. The patient has a history of exposure to animals, including camels.
    A 56 year-old man from the Riyadh region with underlying medical conditions. He became ill on 6 March and was admitted to hospital on 13 March. He is currently in a critical condition. The patient has a history of exposure to animals, including camels.
    A 45 year-old man from the Riyadh region with underlying medical conditions. He became ill on 5 March and was admitted to hospital on 15 March. He is currently in a critical condition. The patient has no history of exposure to animals.
    Globally, from September 2012 to date, WHO has been informed of a total of 206 laboratory-confirmed cases of infection with MERS-CoV, including 86 deaths.

    WHO advice

    Based on the current situation and available information, WHO encourages all Member States to continue their surveillance for severe acute respiratory infections (SARI) and to carefully review any unusual patterns.

    Infection prevention and control measures are critical to prevent the possible spread of MERS-CoV in health care facilities. Health-care facilities that provide for patients suspected or confirmed to be infected with MERS-CoV infection should take appropriate measures to decrease the risk of transmission of the virus from an infected patient to other patients, health-care workers and visitors. Health care workers should be educated, trained and refreshed with skills on infection prevention and control.

    It is not always possible to identify patients with MERS-CoV early because some have mild or unusual symptoms. For this reason, it is important that health-care workers apply standard precautions consistently with all patients – regardless of their diagnosis – in all work practices all the time.

    Droplet precautions should be added to the standard precautions when providing care to all patients with symptoms of acute respiratory infection. Contact precautions and eye protection should be added when caring for probable or confirmed cases of MERS-CoV infection. Airborne precautions should be applied when performing aerosol generating procedures.

    Patients should be managed as potentially infected when the clinical and epidemiological clues strongly suggest MERS-CoV, even if an initial test on a nasopharyngeal swab is negative. Repeat testing should be done when the initial testing is negative, preferably on specimens from the lower respiratory tract.

    Health-care providers are advised to maintain vigilance. Recent travellers returning from the Middle East who develop SARI should be tested for MERS-CoV as advised in the current surveillance recommendations. All Member States are reminded to promptly assess and notify WHO of any new case of infection with MERS-CoV, along with information about potential exposures that may have resulted in infection and a description of the clinical course. Investigation into the source of exposure should promptly be initiated to identify the mode of exposure, so that further transmission of the virus can be prevented.

    People at high risk of severe disease due to MERS-CoV should avoid close contact with animals when visiting farms or barn areas where the virus is known to be potentially circulating. For the general public, when visiting a farm or a barn, general hygiene measures, such as regular hand washing before and after touching animals, avoiding contact with sick animals, and following food hygiene practices, should be adhered to.

    WHO does not advise special screening at points of entry with regard to this event nor does it currently recommend the application of any travel or trade restrictions.

    Sentiment: Buy

  • Early reports[1] compared the virus to severe acute respiratory syndrome (SARS), and it has been referred to as Saudi Arabia's SARS-like virus.[2] Symptoms of MERS-CoV infection include renal failure and severe acute pneumonia, which often result in a fatal outcome. The first patient had a "7-day history of fever, cough, expectoration, and shortness of breath."[1] MERS has an estimated incubation period of 12 days.

    Sentiment: Buy

  • Reply to

    Cytosorbents News Today

    by berthabluefish Apr 8, 2014 8:05 AM
    andy55q andy55q Apr 8, 2014 8:27 AM Flag

    Coronaviruses are a large family of viruses that includes viruses that may cause a range of illnesses in humans, from the common cold to SARS. Viruses of this family also cause a number of animal diseases.

    Middle East respiratory syndrome coronavirus (MERS-CoV)
    This particular strain of coronavirus has not been previously identified in humans. There is very limited information on transmission, severity and clinical impact with only a small number of cases reported thus far.

  • Reply to

    Alot of new photos n Facebook from ISICEM

    by berthabluefish Mar 21, 2014 6:00 AM
    andy55q andy55q Mar 21, 2014 8:45 AM Flag

    SIRS & SEPSIS Symposium at ISICEM 2014 in Brussels (21 photos)
    The evening symposium "SIRS & SEPSIS - new therapeutic approach with CytoSorb" was well visited, thanks again to all guests and speakers. The Q&A session showed the enormous interest of all international guests concerning this topic. Finally everybody could relax with good food, cool drinks and a fantastic view over Brussels! — at Square-Brussels Meeting Centre.

    Sentiment: Buy

  • ‘Liquid biopsy’ could identify multiple neurodegenerative disorders

    Kathy Fay Mahdoubi Mar 19, 2014
    Aethlon and subsidiary Exosome Sciences, both based in San Diego, Calif., announced earlier this month that the companies have isolated blood-borne biomarkers implicated in multiple neurodegenerative diseases.

    A statement from the companies noted that exosomes from the central nervous system have been primarily associated with cerebrospinal fluid, but research led by the partnership has identified exosomes of brain-specific glycoprotein A2B5 and S100B, beta amyloid and tau in peripheral circulation. These exosomes cross the blood brain barrier into the bloodstream and could be a target for diagnostic testing of neurological disease.

    “This advancement represents a new paradigm for brain injuries,” said Exosome Sciences chief scientific officer, Douglas Taylor, MD, in a statement. “In addition to providing definitive diagnosis, the proteomic and transcriptomic characterization of exosomes isolated specifically from the brain will provide a window into the molecular mechanisms underlying acute and chronic brain injuries."

    Major targets for blood testing of these exosomes include Alzheimer’s disease, traumatic brain injury and chronic traumatic encephalopathy (CTE), a progressive disease that is associated with trauma to the brain from military service and blast-injury and professional athletics such as football. Repetitive head trauma is thought to contribute to onset of the disorder.

    Isolated exosomes from peripheral circulation can be unpacked to reveal specific RNA cargoes representing a kind of molecular biopsy for diagnosis, staging of disease and potential therapeutic monitoring.

    “An exosome-based liquid biopsy that could identify the early onset of Alzheimer's disease or CTE in a living person may also unlock the ability to monitor disease progression and set the stage for new therapeutic advances, which could include Aethlon Medical therapeutic devices," CEO of Aethlon Medical and executive chairman of Exosome Sciences Jim Joyce added in the press release.

    Future therapeutic devices would focus on a concept called “peripheral sink,” which theorizes that stripping these elements from circulation leads to a reduction in plaque in the brain and the progression of disease. The two companies have filed for a provisional patent for what they are calling “exosome-based diagnostics and extracorporeal therapies.”

    These concepts are at their earliest stages and are not currently in clinical use. Further study and regulatory approval is required to validate clinical effectiveness for liquid biopsy and subsequent therapeutics for neurodegenerative disease.

    Sentiment: Buy

  • Reply to

    Seriously, I'd be buying right here.

    by warrenbufferzone Mar 17, 2014 10:06 PM
    andy55q andy55q Mar 18, 2014 9:53 AM Flag

    OK, Time line on Company announcement-In Your Opinion

    Sentiment: Buy

  • Reply to

    Seriously, I'd be buying right here.

    by warrenbufferzone Mar 17, 2014 10:06 PM
    andy55q andy55q Mar 18, 2014 9:45 AM Flag

    Ping,How about a hint!!
    ping_pow_princess • Mar 14, 2014 12:33 PM Flag
    I'm aware of a few things through my research, that I'm personally excited about. I'll wait for the company to make their announcements.
    Thank You
    Andy

    Sentiment: Buy

  • Reply to

    Support at $0.23

    by buymyask Mar 14, 2014 11:15 AM
    andy55q andy55q Mar 16, 2014 11:23 AM Flag

    How about a small hint?? You can post it on IHUB.
    Thank You

    Sentiment: Buy

  • Reply to

    Things should get back to normal next week

    by berthabluefish Mar 15, 2014 8:38 AM
    andy55q andy55q Mar 15, 2014 9:33 PM Flag

    Cytokine Removal in Cardiopulmonary Bypass Patients (CytoSorb)
    Estimated Enrollment: 40
    Study Start Date: August 2013
    Estimated Study Completion Date: February 2014
    Estimated Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
    ClinicalTrials.gov Identifier:
    NCT01879176
    First received: June 7, 2013
    Last updated: November 1, 2013
    Last verified: November 2013

    Sentiment: Buy

  • andy55q andy55q Mar 12, 2014 10:42 AM Flag

    Go to CTSO web site for more info on treatment use for Trauma,burns etc.
    CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

    In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

    Sentiment: Buy

  • Seems as if Sloan Kettering has found a way to kill Leukemia cells in the blood. Read to the end, the only side effect seems to be that it works so well, and kills the cells all at once, so the release of toxins becomes a problem.... I believe that's exactly where WE (AEMD and CTSO) come in.
    Chemotherapy-free cancer treatment uses body's own immune system to attack diseased cells
    (NaturalNews) A revolutionary breakthrough in cancer treatment that is being described as a "game-changer" would see the body's own immune system utilized to attack diseased cells, rather than rely on sickening chemotherapy, researchers announced lately.

    Scientists at Memorial Sloan Kettering Cancer Center in New York say they have successfully experimented with the new procedure, using 16 people who had advanced leukemia and had otherwise run out of treatment options. The researchers said the patients underwent targeted T cell therapy, which then eliminated the cancerous cells in most of the patients, CBS News reported.

    Dr. David Agus, a CBS News expert contributor who leads the Westside Cancer Center at the University of Southern California, called the team's work "remarkable research."

    'This was no fluke'

    "They took 16 patients with advanced leukemia, who had failed chemotherapy or not responded at all to chemotherapy, so they classically have weeks to months to live. They took their own immune cells out... and inserted a homing mechanism to target the cancer cells," said Agus. "The cancer cells were growing on their own, unrelentingly, and these immune cells came in and they could target and kill them. They become assassins. So, making their own immune cells become assassins and it worked."

    Study senior author Dr. Renier Brentjens, an oncologist at Memorial Sloan Kettering, told HealthDay News: "First and foremost, we've shown that this isn't a fluke. This is a reliable result. ... We're still very much in the early stages of development. ... [T]his is potentially the first promising new therapy [for advanced B-cell ALL] in a long time."

    In additional comments to Agence France-Presse, Brentjens said, "Basically, what we do is re-educate the T cell in the laboratory with gene therapy to recognize and now kill tumor cells."

    Following 15 years of study on the procedure, Brentjens said that "it seems to really work in patients with this particular type of cancer."

    Of the 16 patients who took part in the study, 14 achieved total remission. But, Agus said, the treatment does not cure cancer on its own.

    "What we know is this cancer comes back and the only way to cure it is with a bone marrow transplant," he said. "You can only go for a bone marrow transplant if you've first eliminated the cancer cells in the blood."

    The research oncologist said the therapy was able to remove cancer cells from the blood effectively, and that "most of the patients were able to go on to transplant." At that point, he said, patients can actually be cured of the disease.

    'Treatment might work too well'

    Some of the biggest problems with current cancer treatments such as chemotherapy are the side effects: The drugs involved in chemotherapy can make patients very sick and weak. And while Agus said all treatments will have some side effects, the new therapy might actually work "too well."

    "These cells kill all of the cancer at once and it's actually the toxins from the dead cancer cells that cause the side effects," he said, adding that, since the initial success among the 16 patients, between 60 and 80 in the U.S. have signed onto trials, which are also being launched in Europe.

    The oncologist said the breakthrough treatment was not possible even a decade ago, because it was built on years of prior trial-and-error involving gene therapy.

    At present, the therapy has not been approved by the U.S. Food and Drug Administration. Agus said the treatment can cost upwards of $100,000 per patient, but he said that cost should decrease as the therapy advances.

    Sentiment: Buy

  • andy55q andy55q Mar 12, 2014 10:05 AM Flag

    RV I posted this on IHUB.

    Sentiment: Buy

  • We are very pleased to invite you to a scientific evening symposium at the 34th ISICEM congress in Brussels. Internationally renowned physicians will inform you on their CytoSorb® experience.

    SIRS and SEPSIS – New therapy with CytoSorb®

    - Overshooting the inflammatory response – The Root of all evil? (Herwig Gerlach, Berlin/Germany)

    - Blood purification in SIRS and Sepsis – A new paradigm (John Kellum, Pittsburgh/US)

    - Clinical experience - Severe Sepsis/Septic Shock and CytoSorb® Therapy (Michael Quintel, Goettingen/Germany)

    - Clinial experience – Post-Cardio-Pulmonar-Bypass-SIRS and CytoSorb® Therapy (Karl Traeger, Ulm/Germany)

    The symposium takes place on Wednesday, March 19th from 6.15pm to 7.45pm in The Arc room. Afterwards it will be our pleasure to invite you to a dinner buffet. Let’s have a drink together in a relaxed atmosphere after a long and certainly enlightening conference day.
    Go to CTSO Facebook for more info

    Sentiment: Buy

SYK
79.05-0.52(-0.65%)Apr 16 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.